---
company: Innoviva, Inc.
ticker: INVA
form: 8-K
filed: 2026-11-04
accepted: 2026-11-04T21:25:58+00:00
accession: 0001193125-26-447366
source: https://www.sec.gov/Archives/edgar/data/1080014/000119312526447366/
---

# Innoviva (INVA) Q3 2026 earnings

## Header

- Company: Innoviva, Inc.
- Reported: 2026-11-04 16:25 AMC ET
- Source: 8-K only — accession 0001193125-26-447366, Item 2.02 + Exhibit 99.1
- Verdict: Revenue grew but net income swung to a loss driven by large equity investment losses.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---:|---:|---|
| EPS (GAAP) | -$1.03 | -179.2% | -9.7% | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Royalty revenue, net | $54.7M | -8.8% | 51.5% | Durable portfolio |
| Net product sales | $49.4M | +4.5% | 46.6% | IST U.S. sales |
| License and other revenue | $2.0M | +231.0% | 1.9% | — |

## Margins and costs

- Gross margin: 79.4% (prior 75.2%, change +4.2 pp)
- Operating expenses: $42.2M (+3.1% YoY)
- One-offs in the quarter: Changes in fair values of equity method investments, net: -$97.6M; Changes in fair values of equity and long-term investments, net: -$41.9M; Income tax benefit (expense): $23.7M
- Effective tax rate: 24.3% (prior-year -10.2%, year-to-date 1.2%)
- Non-GAAP bridge: Adds back changes in fair values of equity method and long-term investments, and income tax benefit/expense to get from GAAP to operating income.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---|
| IST U.S. net product sales | $43.3M | $36.6M | $29.8M | +45% YoY |
| Cash and cash equivalents | $581.4M | $570.4M | $397.5M | +46.1% YoY |
| Share repurchases | 1.2M shares | 1.2M shares | 1.2M shares | Under $125M program |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| IST U.S. net product sales | At least $150M | At least $150M | No change |

## What drove it

- Revenue story: Total revenue decreased 1.6% YoY, driven by a 8.8% decline in royalty revenue, offset by a 4.5% increase in net product sales.
- EPS story: GAAP EPS swung to a loss of -$1.03, driven by a $139.5M swing in equity investment losses and a $31.6M swing in tax benefit.
- One-off check: Equity method investments: -$97.6M; Equity and long-term investments: -$41.9M; Tax benefit: $23.7M.

## The good

- IST U.S. net product sales grew 45% YoY to $43.3M
- Gross margin expanded 4.2 pp to 79.4%
- Operating income grew 21.9% YoY to $42.2M

## The bad

- Royalty revenue declined 8.8% YoY to $54.7M
- Total revenue declined 1.6% YoY to $106.1M
- Net income swung to a loss of $73.9M

## The ugly

- none

## Open questions

- What caused the 8.8% decline in royalty revenue?
- What is the expected timing and magnitude of recovery for the equity method investment losses?
- Why did the equity method investment value drop significantly in Q3 after a gain in Q2?

## Full release

### Innoviva (INVA) earnings release, November 4, 2026

Innoviva, Inc. (INVA) · Form 8-K, Item 2.02 · Filed 2026-11-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1080014/000119312526447366/)

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth

$58.1 million in quarterly revenue from durable royalty portfolio

Returned capital to shareholders through repurchase of 1.2 million shares in Q3 under $125 million buyback program

BURLINGAME, Calif. – Nov 4, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements.

“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales. We are excited about the potential to meaningfully expand the reach of our products and expect operating leverage, supported by sustained fiscal discipline, to strengthen the business’s profitability as revenues grow. Marking another milestone for IST, NUZOLVENCE®, a first-in-class, single-dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea, is now commercially available in the U.S.,” said Pavel Raifeld, Chief Executive Officer of Innoviva.

“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation. To that end, we evaluate new opportunities that can broaden our portfolio and further accelerate growth alongside investments in our high-potential strategic healthcare assets. We also continue to execute on our share repurchase program, reflecting our excitement and conviction in Innoviva’s long-term prospects,” concluded

Mr. Raifeld.

Financial Highlights

Business Highlights

- 2 -

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva

Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®

/BREO®

ELLIPTA® and ANORO®

ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA®

(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO®

(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of

Acinetobacter baumannii-calcoaceticus, XERAVA®

(eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA®

(ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and

NUZOLVENCE®

(zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg.

For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

Forward-looking Statements

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation

Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of

RELVAR®

/BREO®

ELLIPTA®, ANORO®

ELLIPTA®, GIAPREZA®,

XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to

- 3 - shareholders; the development of the LYNX®... (truncated)udies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form

10-K for the year ended December 31, 2025 and Quarterly Reports on Form

10-Q, which are on file with the Securities and Exchange

Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

- 4 -

INNOVIVA, INC.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

- 5 -

INNOVIVA, INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

- 6 -

INNOVIVA, INC.

Cash Flows Summary

(in thousands)

(unaudited)

- 7 -

CONTACTS

Media

Amanda Brown Galgay

Vice President, Communications amanda.galgay@inva.com

Investors

Irwin Tendler

Head of Investor Relations

Executive Director, Corporate

Development investors.relations@inva.com

- 8 -

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (Unaudited) (in thousands))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenue:** | | | | |
| Royalty revenue, net (1) | 54,657 | 59,896 | 166,158 | 181,583 |
| Net product sales | 49,444 | 47,294 | 142,586 | 113,066 |
| License and other revenue | 2,019 | 610 | 14,961 | 2,066 |
| Total revenue | 106,120 | 107,800 | 323,705 | 296,715 |
| Cost of products sold (inclusive of amortization of inventory fair value adjustments) | 15,038 | 25,643 | 52,994 | 45,075 |
| Amortization of acquired intangible assets | 6,700 | 6,618 | 19,880 | 19,640 |
| Gross profit | 84,382 | 75,539 | 250,831 | 232,000 |
| **Operating expenses:** | | | | |
| Selling, general and administrative | 37,015 | 27,291 | 104,024 | 81,194 |
| Research and development | 5,214 | 13,670 | 15,645 | 26,049 |
| Total operating expenses | 42,229 | 40,961 | 119,669 | 107,243 |
| Income from operations | 42,153 | 34,578 | 131,162 | 124,757 |
| Changes in fair values of equity method investments, net | -97,585 | 30,751 | -71,769 | 30,284 |
| Changes in fair values of equity and long-term investments, net | -41,904 | 31,510 | -37,482 | -22,509 |
| Interest and dividend income | 5,316 | 5,472 | 23,902 | 14,935 |
| Interest expense | -5,472 | -4,015 | -16,381 | -13,389 |
| Other expense, net | -118 | -479 | -499 | -2,252 |
| Income (loss) before income taxes | -97,610 | 97,817 | 28,933 | 131,826 |
| Income tax benefit (expense) | 23,722 | -7,909 | 354 | -24,814 |
| Net income (loss) | -73,888 | 89,908 | 29,287 | 107,012 |
| **Net income (loss) per share:** | | | | |
| Basic | -1.03 | 1.3 | 0.4 | 1.65 |
| Diluted | -1.03 | 1.08 | 0.4 | 1.35 |
| **Shares used to compute net income (loss) per share:** | | | | |
| Basic | 72,068 | 69,058 | 73,209 | 64,901 |
| Diluted | 72,068 | 84,964 | 73,969 | 84,576 |

##### Balance Sheet (September 30, 2026 — (unaudited) (in thousands))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Assets** | | |
| Cash and cash equivalents | 581,394 | 550,941 |
| Royalty and product sale receivables | 102,130 | 93,317 |
| Inventory | 42,838 | 39,172 |
| Prepaid expense and other current assets | 37,225 | 28,358 |
| Current portion of ISP Fund investments | 8,667 | 15,727 |
| Property and equipment, net | 2,038 | 1,555 |
| Equity method and equity and long-term investments | 526,791 | 598,223 |
| Capitalized fees | 45,770 | 56,138 |
| Right-of-use assets | 10,100 | 10,929 |
| Goodwill | 17,905 | 17,905 |
| Intangible assets | 162,276 | 182,156 |
| Other assets | 792 | 40,744 |
| Total assets | 1,537,926 | 1,635,165 |
| **Liabilities and stockholders’ equity** | | |
| Other current liabilities | 44,795 | 43,808 |
| Accrued interest payable | 231 | 1,618 |
| Deferred revenue | 5,004 | 4,270 |
| Convertible senior notes, due 2028, net | 258,822 | 257,731 |
| Deferred tax liabilities, net | 6,914 | 31,793 |
| Income tax payable, long term | 19,406 | 57,013 |
| Other long term liabilities | 65,236 | 66,091 |
| Stockholders’ equity | 1,137,518 | 1,172,841 |
| Total liabilities and stockholders’ equity | 1,537,926 | 1,635,165 |

##### Cash Flow (Nine Months Ended September 30, — (unaudited) (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| Net cash provided by operating activities | 128,952 | 142,417 |
| Net cash provided by (used in) investing activities | -23,685 | 16,860 |
| Net cash provided by (used in) financing activities | -74,814 | 12,272 |
| Net change | 30,453 | 171,549 |
| Cash and cash equivalents at beginning of period | 550,941 | 304,964 |
| Cash and cash equivalents at end of period | 581,394 | 476,513 |
